Clinical trial
Safety and Efficacy Study of the Trifunctional Antibody Ertumaxomab to Treat…
NCT00351858 · Neovii Biotech, Industry · Terminated
Key facts
| NCT number | NCT00351858 |
|---|---|
| Title | Safety and Efficacy Study of the Trifunctional Antibody Ertumaxomab to Treat Patients With Advanced or Metastatic Breast Cancer |
| Official title | Phase II Study of the Trifunctional Anti-HER-2/Neu x Anti-CD3 Antibody Ertumaxomab for Hormone Therapy Refractory Patients With Her-2/Neu 1+ or 2+ Expressing Advanced or Metastatic Breast Cancer |
| Acronym | IV REXBC 02 |
| Lead sponsor | Neovii Biotech, Industry |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Breast Neoplasms, Breast Cancer |
| Intervention type | Drug |
| Interventions | ertumaxomab |
| Enrollment | 40 |
| Start date | Jul 1, 2006 |
| Completion | Feb 1, 2009 |
| First posted | Jul 13, 2006 |
| Last update posted | May 1, 2015 |
| Countries | Belgium |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: